Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apadamtase alfa - Takeda

Drug Profile

Apadamtase alfa - Takeda

Alternative Names: ADAMTS13, recombinant-krhn - Takeda; ADZYNMA; BAX-930; Cinaxadamtase alfa; rADAMTS-13; Recombinant ADAMTS13; Recombinant-A disintegrin and mellatoproteinase with thrombospondin type-1 motifs-13; SHP-655; TAK 755

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken
  • Developer Takeda
  • Class Antithrombotics; Disintegrins; Enzymes; Metalloproteases; Recombinant proteins
  • Mechanism of Action ADAMTS13 protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura; Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Thrombotic thrombocytopenic purpura
  • Phase I Vaso-occlusive crisis

Most Recent Events

  • 26 Mar 2024 Registered for Thrombotic thrombocytopenic purpura (In adolescents, In children, In the elderly, In adults) in Japan (IV)
  • 01 Feb 2024 Apadamtase alfa is still in phase-I trial for Vaso-occlusive-crisis in USA (IV, Infusion) (Takeda pipeline; February 2024)
  • 09 Dec 2023 Adverse events and pharmacokinetics data from a phase-I RAISE-UP clinical trial in Vaso-occlusive crisis related to sickle cell anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top